The stock has a 36-month beta value of 1.65. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for XERS is 125.56M, and at present, short sellers hold a 7.16% of that float. On April 17, 2024, the average trading volume of XERS was 1.99M shares.
XERS) stock’s latest price update
Xeris Biopharma Holdings Inc (NASDAQ: XERS)’s stock price has gone decline by -2.70 in comparison to its previous close of 1.85, however, the company has experienced a -10.89% decrease in its stock price over the last five trading days. Seeking Alpha reported 2024-03-30 that Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a “Top Idea” in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growth. Risks include competition from larger healthcare companies and the FDA approval of a generic version of one of Xeris’ products, Keveyis.
XERS’s Market Performance
XERS’s stock has fallen by -10.89% in the past week, with a monthly drop of -19.28% and a quarterly drop of -32.08%. The volatility ratio for the week is 5.95% while the volatility levels for the last 30 days are 5.10% for Xeris Biopharma Holdings Inc. The simple moving average for the past 20 days is -12.88% for XERS’s stock, with a -19.20% simple moving average for the past 200 days.
Analysts’ Opinion of XERS
Many brokerage firms have already submitted their reports for XERS stocks, with Oppenheimer repeating the rating for XERS by listing it as a “Outperform.” The predicted price for XERS in the upcoming period, according to Oppenheimer is $5 based on the research report published on March 28, 2024 of the current year 2024.
Craig Hallum, on the other hand, stated in their research note that they expect to see XERS reach a price target of $4.50. The rating they have provided for XERS stocks is “Buy” according to the report published on August 28th, 2023.
Jefferies gave a rating of “Buy” to XERS, setting the target price at $4 in the report published on October 21st of the previous year.
XERS Trading at -27.82% from the 50-Day Moving Average
After a stumble in the market that brought XERS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.79% of loss for the given period.
Volatility was left at 5.10%, however, over the last 30 days, the volatility rate increased by 5.95%, as shares sank -15.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.53% lower at present.
During the last 5 trading sessions, XERS fell by -10.89%, which changed the moving average for the period of 200-days by -23.40% in comparison to the 20-day moving average, which settled at $2.0495. In addition, Xeris Biopharma Holdings Inc saw -23.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XERS starting from Schmid John P., who purchase 4,500 shares at the price of $2.16 back on Mar 14 ’24. After this action, Schmid John P. now owns 11,000 shares of Xeris Biopharma Holdings Inc, valued at $9,720 using the latest closing price.
SHERMAN JEFFREY W, the Director of Xeris Biopharma Holdings Inc, purchase 5,400 shares at $1.87 during a trade that took place back on Nov 27 ’23, which means that SHERMAN JEFFREY W is holding 5,400 shares at $10,098 based on the most recent closing price.
Stock Fundamentals for XERS
Current profitability levels for the company are sitting at:
- -0.27 for the present operating margin
- 0.81 for the gross margin
The net margin for Xeris Biopharma Holdings Inc stands at -0.38. The total capital return value is set at -0.18. Equity return is now at value -324.20, with -18.17 for asset returns.
Based on Xeris Biopharma Holdings Inc (XERS), the company’s capital structure generated 1.04 points at debt to capital in total, while cash flow to debt ratio is standing at -0.25. The debt to equity ratio resting at -28.67. The interest coverage ratio of the stock is -3.41.
Currently, EBITDA for the company is -30.85 million with net debt to EBITDA at -4.58. When we switch over and look at the enterprise to sales, we see a ratio of 2.53. The receivables turnover for the company is 4.18for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.
Conclusion
To sum up, Xeris Biopharma Holdings Inc (XERS) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
